Calculate Your AIP and Unlock Hidden Heart Kidney Metabolic Risk

🎧 ▶️ Press the play button below to listen in English.

🇨🇳 中文（简体）

请按下方的播放按钮收听。

I. Introduction: The Hidden Connection Between Your Heart, Kidneys, and Metabolism

For decades, we’ve been taught to think of our organs as separate entities. You go to a heart doctor for your heart and a kidney doctor for your kidneys. But the human body doesn’t work in silos. It operates as a deeply interconnected network, and when one critical system begins to fail, it can trigger a domino effect that brings others down with it.

Nowhere is this connection more critical than in the relationship between your heart, your kidneys, and your metabolism—the system that governs your weight, blood sugar, and energy.

A growing body of research shows that metabolic problems like obesity and diabetes don’t just stay in the blood; they directly damage the heart’s arteries and the kidneys’ delicate filtering units. Conversely, failing kidneys can strain the heart, leading to a dangerous downward spiral.

To address this, the American Heart Association recently introduced a new framework called Cardiovascular-Kidney-Metabolic (CKM) Syndrome. Think of CKM syndrome as an umbrella term that describes the entire spectrum of this interconnected disease process.

The CKM Syndrome ranges from Stage 0 (no risk factors) to Stage 4 (full-blown cardiovascular disease with kidney disease). This final, most severe stage—where the heart and kidneys are failing together in a vicious cycle—is known as Cardiorenal Syndrome (CRS). It represents the “destination” at the end of a long, preventable journey.

The challenge has always been identifying who is on the fast track to that destination before they arrive. What if a simple, inexpensive blood test could tell you not only if you are already at high risk for cardiorenal syndrome, but also predict your chances of dying from it years in the future?

Recent, large-scale studies suggest that such a tool exists. It’s called the Atherogenic Index of Plasma (AIP), and it may be one of the most powerful yet underutilized predictors of your future health.

II. What is the Atherogenic Index of Plasma (AIP)?

If you’ve ever had your cholesterol checked, you’re familiar with the standard lipid panel: Total Cholesterol, LDL (the “bad” cholesterol), HDL (the “good” cholesterol), and Triglycerides (a type of fat in your blood).

The AIP isn’t a separate test. Instead, it’s a clever calculation that uses two of these numbers—Triglycerides (TG) and HDL cholesterol (HDL-C) —to reveal something the others can’t.

The Simple Formula:
AIP = log (Triglycerides / HDL-C)

You don’t need to remember the logarithm. What you need to remember is this: as your AIP number goes up, so does your risk.

Why is AIP so powerful?
Because it doesn’t just measure how much cholesterol you have, it also assesses the quality and danger of your cholesterol profile. A high AIP signals a condition called atherogenic dyslipidemia. This dangerous combination is characterized by two key problems:

• An Overabundance of “Small, Dense” LDL: High triglycerides are a marker for an increase in small, dense LDL particles. Unlike their “fluffy” counterparts, these small particles are easily oxidized and can burrow into your artery walls, forming the foundation of dangerous plaque. Standard LDL tests often miss this distinction.

• A Shortage of “Good” HDL: HDL is responsible for reverse cholesterol transport—essentially, it scrubs excess “bad” cholesterol from your arteries and carries it back to your liver for removal. A low HDL-C level in the AIP calculation means this protective “cleanup crew” is understaffed.

In essence, the AIP captures the perfect storm for atherosclerosis: you have more of the dangerous, artery-clogging particles (due to high TG) and fewer of the protective, artery-cleaning particles (due to low HDL). This makes it a uniquely valuable snapshot of your true cardiovascular and metabolic health.

III. Study 1: AIP Predicts if You Already Have Cardiorenal Syndrome (The “Destination”)

Now that we understand what AIP measures, the critical question becomes: Does this snapshot of your lipid quality actually translate to real-world disease? A landmark study published in 2025 set out to answer exactly that, focusing on the most severe endpoint of the CKM spectrum: Cardiorenal Syndrome (CRS). [1]

Researchers analyzed data from the National Health and Nutrition Examination Survey (NHANES), a large, nationally representative sample of the U.S. population. They examined records from over 35,000 adults, comparing their AIP levels against the presence of CRS—defined as having both cardiovascular disease (like heart failure, coronary disease, or stroke) and chronic kidney disease simultaneously.

The results were striking. After accounting for other risk factors like age, smoking, and diabetes, the study found a clear, dose-dependent relationship: the higher your AIP, the more likely you were to already have Cardiorenal Syndrome.

• The Key Number: Individuals with the highest AIP levels were 62% more likely to have CRS compared to those with the lowest AIP levels.

• The Trend: Risk increased steadily across AIP quartiles, confirming that this isn’t an “all-or-nothing” effect. Even moderately elevated AIP levels signaled increased danger.

Perhaps the most fascinating—and clinically useful—finding emerged when the researchers dug deeper into specific subgroups. They discovered a powerful interaction with hypertension.

• The Surprising Twist: The link between high AIP and CRS was significantly stronger in people without high blood pressure.

• What This Means: For individuals with hypertension, the damage from high blood pressure is so profound that it can overshadow other risk factors. But in people who have not yet developed high blood pressure—those who might consider themselves relatively healthy—a high AIP level acts as a critical early warning signal. It identifies individuals who are silently on the path toward organ failure, even though their blood pressure numbers look good.

The Simple Takeaway: A high AIP is not just a theoretical risk on a piece of paper. In this study, it was directly linked to the actual, physical coexistence of heart and kidney disease. If your AIP is elevated, your body may already be fighting a battle you don’t know about, even if other metrics like blood pressure appear normal.

---

IV. Study 2: AIP Predicts Your Future Risk of Death from CKM Syndrome (The “Journey”)

If the first study answered the question “Is high AIP linked to current disease?”, a second major study, also published in 2025, tackled an even more pressing one: “Can AIP tell me what will happen to me in the future?” [2]

This study took a different longitudinal approach. Researchers again used the NHANES database, but this time they focused on more than 15,700 individuals with CKM syndrome and tracked them for a median of more than 7 years, linking their baseline AIP levels to mortality data from the National Death Index. They wanted to know: Does your AIP today predict your risk of dying tomorrow?

The answer was a definitive yes.

After adjusting for a wide range of demographic, lifestyle, and clinical factors, the study revealed that participants with the highest AIP levels faced significantly higher risks of death compared to those with the lowest levels.

• All-Cause Mortality: Individuals in the highest AIP group had a 19% higher risk of dying from any cause during the follow-up period.

• Cardiovascular Mortality: The impact on heart-specific deaths was even more dramatic. Those with the highest AIP levels had a 38% higher risk of dying from cardiovascular disease—primarily heart attacks, strokes, and heart failure.

But the study’s most important contribution to our understanding of CKM syndrome came from its staging analysis. Remember that CKM syndrome is divided into stages, from 0 (no risk) to 4 (clinical disease). The researchers divided participants into “non-advanced” (Stages 0-2) and “advanced” (Stages 3-4) groups and analyzed them separately.

• The Critical Finding: AIP levels were associated with cardiovascular mortality in both non-advanced and advanced stages. In the non-advanced group, where people have metabolic risk factors and maybe early kidney disease but no symptoms, AIP was still predicting their risk of ultimately dying from heart disease.

I discussed how AIP predicts heart attacks in young people in AIP Predicts Heart Attack Risk In Younger Adults and how AIP can tell if someone will have a heart attack even if they have a non-obstructing coronary artery disease. Your Angiogram Was ‘Fine’—So Why The Heart Attack? The AIP Clue In MINOCA

• Why This is a Game-Changer: This means AIP can identify high-risk individuals long before they ever feel sick. Most people in CKM Stage 1 or 2 are walking around, living their lives, unaware that a dangerous process is underway. Their doctors might tell them to “eat better and exercise,” but they aren’t prescribed the powerful medications that could alter their trajectory. This study suggests that AIP could be the tool that changes that—the red flag that moves a patient from “watch and wait” to “aggressive prevention.”

The Simple Takeaway: AIP is not just a marker of where you are today; it is a powerful predictor of where you are headed. A high AIP signals a significantly higher likelihood of dying from heart disease, and it can deliver this warning years or even decades before traditional symptoms appear, offering a priceless window of opportunity for intervention.

V. Your Action Plan: What to Do With This Information

By now, the message is clear: AIP is a powerful tool that can reveal hidden risk and predict future danger. But knowledge is only useful if it leads to action. This section is designed to empower you to take control of your health using this information. Think of it not as a reason to worry, but as an opportunity to intervene—early and effectively.

---

Step 1: Find Your AIP

The first step is the easiest. You cannot act on what you do not know.

• Get the Blood Test: At your next routine check-up or physical, ask your doctor for a standard lipid panel. This is a common, inexpensive blood test typically ordered as part of annual wellness visits.
• Get Your Numbers: Once the results come back, you will need two specific values from that panel:
  • Triglycerides (TG): Measured in mg/dL (in the U.S.) or mmol/L (internationally).
  • HDL Cholesterol (HDL-C): Also measured in mg/dL or mmol/L.
• Calculate Your AIP: You can ask your doctor to calculate it, or you can do it yourself in seconds using the calculator below. Simply enter your numbers, and the tool will do the math and interpret your risk level.

Try It Yourself: Calculate Your AIP

This simple tool uses the standard formula AIP = log10(TG / HDL-C). Enter your numbers in mg/dL (the standard unit in the U.S.) to see your result and what it means.

Step 2: Interpret Your Number

Once you have your AIP value, you need to know what it means. The medical literature generally categorizes AIP risk as follows:

• Low Risk (AIP < 0.11): Your lipid profile suggests a favorable balance. Your triglyceride levels are relatively low compared to your HDL, indicating fewer small, dense LDL particles and a robust “cleanup crew” of protective HDL.

• Intermediate Risk (AIP 0.11 – 0.21): You are in a gray zone. Your lipid balance is starting to tip toward a more atherogenic profile. This is the “danger zone” where proactive lifestyle changes can have the most significant impact and potentially reverse the trajectory before it worsens.

• High Risk (AIP > 0.21): This is a red flag. Your profile suggests a predominance of small, dense LDL particles and insufficient HDL. According to the studies we reviewed, this level is associated with a significantly higher likelihood of existing cardiorenal syndrome and a 38% increased risk of future cardiovascular death. This result warrants a serious conversation with your healthcare provider.

---

Step 3: Take Preventive Measures

Discovering you have an elevated AIP is not a life sentence; it is a call to action. Unlike your genetic code, your AIP is highly modifiable through lifestyle and medical intervention.

Lifestyle Changes That Work:

Because AIP is driven by the balance between triglycerides and HDL, your focus should be on lowering triglycerides and raising HDL.

• To Lower Triglycerides (TG):
  • Reduce Sugar and Refined Carbs: This is the single most effective dietary change. Cut back on sugary sodas, fruit juices, white bread, pasta, pastries, and candy. Your body converts excess sugar and refined carbohydrates directly into triglycerides.
  • Increase Omega-3 Fatty Acids: Found in fatty fish like salmon, mackerel, sardines, as well as flaxseeds and walnuts. Consider a high-quality fish oil supplement after discussing it with your doctor.
  • Limit Alcohol: For some people, even modest alcohol consumption can significantly raise triglyceride levels.
• To Raise HDL Cholesterol (HDL-C):
  • Exercise Regularly: Aerobic exercise (brisk walking, running, swimming, cycling) is one of the most potent ways to boost HDL. Aim for at least 150 minutes of moderate-intensity activity per week.
  • Choose Healthy Fats: Replace trans fats (fried foods, processed snacks) and saturated fats with monounsaturated and polyunsaturated fats found in olive oil, avocados, nuts, and seeds.
  • If You Smoke, Quit: Smoking dramatically lowers HDL and damages blood vessels. Quitting is one of the fastest ways to improve your HDL levels and overall vascular health.

Medical Guidance: Partner With Your Doctor

Do not try to manage this alone. Share your AIP result with your healthcare provider. They can help you create a comprehensive plan that may include:

• Medications: Depending on your overall risk profile (age, family history, blood pressure, blood sugar), your doctor may recommend statins or newer, groundbreaking medications like SGLT2 inhibitors or GLP-1 receptor agonists. These drugs have been shown in clinical trials to not only improve lipid profiles but also directly protect the heart and kidneys, making them ideal for patients on the CKM spectrum.
• Monitoring: Your doctor can recommend a schedule for re-checking your lipid panel to track your progress and adjust your treatment plan as needed.

---

VI. Conclusion

The way we think about chronic disease is evolving. We are moving away from treating individual organs in isolation and toward a more holistic understanding of how the heart, kidneys, and metabolism function as an integrated system.

The introduction of Cardiovascular-Kidney-Metabolic (CKM) Syndrome as a clinical framework is a major step forward, acknowledging that conditions like obesity, diabetes, kidney disease, and heart failure are not separate problems but interconnected stages of a single underlying process.

Within this new paradigm, the Atherogenic Index of Plasma (AIP) emerges as an unexpectedly simple yet profoundly powerful tool. As the two recent studies we’ve explored demonstrate, AIP does two critical things:

1. It identifies individuals who are already at the most severe stage of the CKM spectrum—Cardiorenal Syndrome—with those in the highest AIP group being 62% more likely to have both heart and kidney failure.
2. It predicts future risk with startling precision, signaling a 38% higher chance of cardiovascular death years before traditional symptoms appear, even in people who are still in the “non-advanced” stages of CKM syndrome.

The beauty of AIP lies in its accessibility. It doesn’t require expensive genetic testing or advanced imaging. It can be calculated from a standard cholesterol test that millions of people already get each year. Yet, for most, this powerful number goes unreported and unexamined.

The Final Call to Action:

You now have knowledge that can change the trajectory of your health. Don’t wait for symptoms to appear. Don’t assume that normal blood pressure or a normal weight means you are safe.

At your next check-up, ask your doctor for your lipid panel results. Plug your Triglycerides and HDL into the calculator above. Know your AIP.

If it is elevated, you have been given a gift: a warning years in advance. Use that time wisely. Take action. Talk to your doctor, adjust your lifestyle, and consider the available medical options. Your heart and your kidneys are deeply connected, and by monitoring this simple index, you can take proactive steps today to protect them both—and safeguard your future for years to come.

Don’t Get Sick!

About Dr. Jesse Santiano, MD

Dr. Santiano is a retired internist and emergency physician with extensive clinical experience in metabolic health, cardiovascular prevention, and lifestyle medicine. He reviews all medical content on this site to ensure accuracy, clarity, and safe application for readers. This article is for educational purposes and is not a substitute for personal medical care.

💡 Support This Work

Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.

🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!

Follow me on Facebook, Gab, Twitter (formerly known as X), and Telegram.

Related:

1. Depression And Cardiovascular Risk: Calculate Your AIP Score Now
2. AIP Cholesterol Test: Predict Dementia Risk With One Simple Number
3. AIP and Mood Disorders – The Lipid Link to Depression and Bipolar Disorder
4. How to Use AIP in Prediabetes and Type 2 Diabetes to Prevent Major Heart Events
5. Your Angiogram Was ‘Fine’—So Why The Heart Attack? The AIP Clue In MINOCA
6. Low LDL But Heart Attack Risk: Check AIP Now
7. AIP Predicts Heart Attack Risk In Younger Adults
8. AIP and Cardiovascular and Atherosclerotic Risk: A Simple TG/HDL Number That Tracks Artery Health
9. Atherogenic Index (AIP): Meaning, Clinical Uses and Calculator
10. 15 Diseases Predicted By The Atherogenic Index Of Plasma

References:

1. Xu S, Hu J, Ouyang Z, Yuan M, Zheng Y, Liu X, Shen Y. Elevated atherogenic index of plasma is associated with increased cardiorenal syndrome prevalence: a cross-sectional study. Ren Fail. 2025 Dec;47(1):2472037. doi: 10.1080/0886022X.2025.2472037. Epub 2025 Mar 2. PMID: 40025821; PMCID: PMC11878164. https://pubmed.ncbi.nlm.nih.gov/40025821/
2. Zheng Q, Cao Z, Teng J, Lu Q, Huang P, Zhou J. Association between atherogenic index of plasma with all-cause and cardiovascular mortality in individuals with Cardiovascular-Kidney-Metabolic syndrome. Cardiovasc Diabetol. 2025 Apr 26;24(1):183. doi: 10.1186/s12933-025-02742-4. PMID: 40287685; PMCID: PMC12034140.

Disclaimer:
This article is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions based on the TyG Index or other biomarkers.

© 2018 – 2025 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment

As an Amazon Associate, I earn from qualifying purchases